MOVIPREP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MOVIPREP (MOVIPREP).
MOVIPREP is an osmotic laxative combination containing macrogol (polyethylene glycol) 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, and sodium ascorbate. The high-dose polyethylene glycol creates an osmotic gradient that retains water in the colon, increasing intraluminal pressure and stimulating peristalsis, leading to bowel evacuation. Ascorbic acid and sodium ascorbate enhance the osmotic effect and reduce the required electrolyte load.
| Metabolism | Macrogol is not metabolized; it is excreted unchanged primarily in feces. Ascorbic acid is metabolized via oxidation to dehydroascorbic acid and further to oxalate and other metabolites. Sodium sulfate is excreted unchanged in urine. |
| Excretion | MOVIPREP (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is minimally absorbed systemically; the non-absorbed fraction is eliminated fecally. The small absorbed fraction (<0.2%) is primarily excreted renally as unchanged PEG 3350 and ascorbic acid metabolites. |
| Half-life | Not applicable due to minimal systemic absorption; PEG 3350 has a terminal elimination half-life of approximately 1–2 hours in the small amount absorbed, but this is clinically irrelevant. |
| Protein binding | Negligible (<1%) due to minimal absorption and high water solubility; PEG 3350 does not bind significantly to plasma proteins. |
| Volume of Distribution | Not clinically meaningful; for the absorbed fraction, Vd of PEG 3350 is approximately 0.1 L/kg, indicating confinement to extracellular fluid; ascorbic acid has Vd of ~0.4 L/kg, but values are not relevant to clinical effect. |
| Bioavailability | Oral route: Bioavailability is extremely low (<0.2%) due to negligible gastrointestinal absorption; local colonic effect is primary without significant systemic bioavailability. |
| Onset of Action | Oral administration: Onset of bowel cleansing typically begins within 1–2 hours after the first dose, with maximal effect within 2–4 hours; divided dosing regimen (two doses) yields first bowel movement approximately 1 hour after the first dose. |
| Duration of Action | Bowel cleansing effect persists for the duration of the dosing regimen (usually 6–8 hours total for split-dose regimen); clinical effect resolves after completion of the last dose and passage of clear fluid effluent. |
Adults: 2 sachets (each containing macrogol 3350 100g, sodium ascorbate 8.8g, ascorbic acid 2.7g, sodium sulfate 7.5g, potassium chloride 1.5g, sodium chloride 2.5g) dissolved in 1 liter of water each, taken as two separate doses: first dose in the evening before colonoscopy, second dose the next morning. Route: oral.
| Dosage form | FOR SOLUTION |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of fluid and electrolyte disturbances. For GFR 30-60 mL/min/1.73m², use with caution and monitor electrolytes. |
| Liver impairment | No specific dose adjustment for hepatic impairment per manufacturer. Use with caution in severe hepatic impairment (Child-Pugh C) due to potential for ascites and fluid shifts. |
| Pediatric use | Not recommended for children <18 years; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required, but monitor for fluid and electrolyte disturbances, and ensure adequate hydration due to higher risk of renal impairment and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MOVIPREP (MOVIPREP).
| Breastfeeding | Polyethylene glycol (PEG) and its components are minimally absorbed systemically; therefore, passage into breast milk is expected to be negligible. The manufacturer recommends caution due to lack of human lactation data. The M/P ratio has not been established. High doses may cause diarrhea in the infant via milk. It is advised to consider alternatives or pump and discard for 24-48 hours after administration. |
| Teratogenic Risk | MOVIPREP is a bowel preparation agent containing polyethylene glycol 3350, sodium sulfate, ascorbic acid, and electrolytes. The manufacturer cites no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 2 times the human dose. Based on limited human data and lack of systemic absorption, the risk is considered low; however, it is generally avoided during pregnancy unless clearly needed, especially in the first trimester due to theoretical risks of electrolyte disturbances and dehydration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Gastrointestinal obstruction or perforation","Ileus","Gastric retention","Toxic colitis or toxic megacolon","Hypersensitivity to any component of MOVIPREP"]
| Precautions | ["Risk of fluid and electrolyte disturbances (hypokalemia, hyponatremia, hypernatremia, hypocalcemia), especially in patients with renal impairment, dehydration, or those taking diuretics or ACE inhibitors","Serious fluid shifts may cause seizures (including generalized tonic-clonic) and arrhythmias","Gastric retention or gastrointestinal obstruction may lead to regurgitation or aspiration","Use with caution in patients with severe ulcerative colitis, toxic megacolon, or ileus","May impair absorption of oral medications taken within 1 hour of administration","Hypersensitivity reactions including anaphylaxis have been reported"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of dehydration, electrolyte imbalances (sodium, potassium, chloride, bicarbonate), and renal function during and after use. In pregnancy, increased monitoring of fetal heart rate and maternal fluid balance is recommended due to potential for hypovolemia. Assess for nausea, vomiting, abdominal distension, or allergic reactions. |
| Fertility Effects | No specific studies on fertility effects have been conducted. Based on its mechanism and lack of systemic absorption, MOVIPREP is unlikely to affect fertility. However, acute electrolyte disturbances from purging could theoretically transiently impact menstrual cycle or spermatogenesis, but no evidence exists. |